Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 12 , ISSUE S1 ( July, 2022 ) > List of Articles

REVIEW ARTICLE

Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease

Ananta Shrestha, Shrijana Pradhananga

Keywords : Holistic approach, Lifestyle intervention, Multistysemic disease, Nonalcoholic fatty liver disease

Citation Information : Shrestha A, Pradhananga S. Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2022; 12 (S1):S51-S58.

DOI: 10.5005/jp-journals-10018-1359

License: CC BY-NC 4.0

Published Online: 10-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Nonalcoholic fatty liver disease (NAFLD), in a few decades, is expected to be the commonest cause of end-stage liver disease and liver cancer surpassing all other etiologies. Urbanization and modern lifestyle have led to global epidemic of NAFLD with alarming prevalence rates across the globe. Its multisystemic involvement manifests as metabolic syndrome, diabetes, cardiovascular disease, end-stage liver disease, and hepatic and extrahepatic malignancies. The absence of promising therapy for halting disease progression in NAFLD is a challenge that is not only limited to liver disease but also other organs involved. It is unrealistic to expect any significant impact of pharmacotherapies in overall survival of NAFLD patients, given that the morbidity and mortality in these patients are contributed by conditions other than that of liver. Liver-centric approach in managing NAFLD will be futile unless the problem is dealt in a holistic manner. Lifestyle modifications have been repeatedly appraised in prevention and treatment of various diseases linked to metabolic syndrome including NAFLD. Despite being inexpensive and highly efficacious in prevention and treatment of different manifestations of NAFLD, lifestyle intervention often fails to gather sufficient interest among patients and physicians alike. This review intends to highlight pleiotropic nature of this disease, limitations of currently available pharmacotherapies and evidence that emphasizing lifestyle intervention is the only way to holistically deal in patients with NAFLD.


PDF Share
  1. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4(5):389–398. DOI: 10.1016/S2468-1253(19)30039-1.
  2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. DOI: 10.1002/hep.28431.
  3. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology 2016;64(1):19–22. DOI: 10.1002/hep.28524.
  4. Patel YA, Berg CL, Moylan CA. Nonalcoholic fatty liver disease: key considerations before and after liver transplantation. Dig Dis Sci 2016;61(5):1406–1416. DOI: 10.1007/s10620-016-4035-3.
  5. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17(4):748–755.e3. DOI: 10.1016/j.cgh.2018.05.057.
  6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1):113–121. DOI: 10.1053/j.gastro.2005.04.014.
  7. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149(2):389–97.e10. DOI: 10.1053/j.gastro.2015.04.043.
  8. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865–873. DOI: 10.1002/hep.21327.
  9. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(Suppl 1):S47–S64. DOI: 10.1016/j.jhep.2014.12.012.
  10. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37(4):917–923. DOI: 10.1053/jhep.2003.50161.
  11. Motamed N, Rabiee B, Poustchi H, et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol 2017;41(1):31–38. DOI: 10.1016/j.clinre.2016.07.005.
  12. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008;49(4):600–607. DOI: 10.1016/j.jhep.2008.06.012.
  13. Sung KC, Wild SH, Kwag HJ, et al. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012;35(11):2359–2364. DOI: 10.2337/dc12-0515.
  14. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6(11):903–913. DOI: 10.1016/S2468-1253(21)00308-3.
  15. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 2017;S0168–8278(17)32294–32298. DOI: 10.1016/j.jhep.2017.09.012.
  16. Allen AM, Hicks SB, Mara KC, et al. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity–a longitudinal cohort study. J Hepatol 2019;71(6):1229–1236. DOI: 10.1016/j.jhep.2019.08.018.
  17. Shen H, Lipka S, Kumar A, et al. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol 2014;5(6):440–446. DOI: 10.3978/j.issn.2078-6891.2014.061.
  18. Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med 2019;17(1):95. DOI: 10.1186/s12916-019-1321-x.
  19. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48(7):696–703. DOI: 10.1111/apt.14937.
  20. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10(12):1342–1359.e2. DOI: 10.1016/j.cgh.2012.10.001.
  21. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675–1685. DOI: 10.1056/NEJMoa0907929.
  22. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357. DOI: 10.1002/hep.29367.
  23. Marchesini G, Day ChP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–1402. DOI: 10.1016/j.jhep.2015.11.004.
  24. Curry SJ, Krist AH, Owens DK, et al. Screening for cardiovascular disease risk with electrocardiography: US preventive services task force recommendation statement. ournal of the American Medical Association 2018;319(22):2308–2314. DOI: 10.1001/jama.2018.6848.
  25. Soldera J, Camazzola F, Rodríguez S, et al. Dobutamine stress echocardiography, myocardial perfusion scintigraphy, invasive coronary angiography, and post-liver transplantation events: systematic review and meta-analysis. Clin Transplant 2018;32(4):e13222. DOI: 10.1111/ctr.13222.
  26. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889–2934. DOI: 10.1016/j.jacc.2013.11.002.
  27. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2021. DOI: 10.1136/gutjnl-2021-324191.
  28. Wong MC, Ching JY, Chan VC, et al. Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history. Int J Cancer 2016;138(3):576–583. DOI: 10.1002/ijc.29809.
  29. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018;67(1):6–19. DOI: 10.1136/gutjnl-2017-314924.
  30. Joka D, Wahl K, Moeller S, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012;55(2):455–464. DOI: 10.1002/hep.24734.
  31. Tanwar S, Trembling PM, Guha IN, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013;57(1):103–111. DOI: 10.1002/hep.26030.
  32. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441–1447. DOI: 10.1136/gut.2007.146019.
  33. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104–1112. DOI: 10.1016/j.cgh.2009.05.033.
  34. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317–1325. DOI: 10.1002/hep.21178.
  35. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51(2):454–462. DOI: 10.1002/hep.23312.
  36. Dahl JJ, Pinton GF, Palmeri ML, et al. A parallel tracking method for acoustic radiation force impulse imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2007;54(2):301–312. PMID: 17328327.
  37. Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011;55(3):666–672. DOI: 10.1016/j.jhep.2010.12.019.
  38. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58(5):1007–1019. DOI: 10.1016/j.jhep.2012.11.021.
  39. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394(10215):2184–2196. DOI: 10.1016/S0140-6736(19)33041-7.
  40. Samala N, Desai A, Vilar-Gomez E, et al. Decreased quality of life is significantly associated with body composition in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18(13):2980–2988.e4. DOI: 10.1016/j.cgh.2020.04.046.
  41. Golabi P, Otgonsuren M, Cable R, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes 2016;14:18. DOI: 10.1186/s12955-016-0420-z.
  42. Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol 2017;51(3):254–260. DOI: 10.1097/MCG.0000000000000567.
  43. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65(5):1557–1565. DOI: 10.1002/hep.29085.
  44. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67(4):829–846. DOI: 10.1016/j.jhep.2017.05.016.
  45. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149(2):367–378.e5; quiz e14–e15. DOI: 10.1053/j.gastro.2015.04.005.
  46. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63(25 Pt B):2985–3023. DOI: 10.1161/01.cir.0000437739.71477.ee.
  47. Goldberg RB, Mather K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol 2012;32(9):2077–2090. DOI: 10.1161/ATVBAHA.111.241893.
  48. Nakanishi N, Hashimoto Y, Okamura T, et al. A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep 2021;11(1):19992. DOI: 10.1038/s41598-021-99036-y.
  49. Wing RR, Wing RR, Bahnson JL, et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170(17):1566–1575. DOI: 10.1001/archinternmed.2010.334.
  50. Haufe S, Haas V, Utz W, et al. Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. Diabetes Care 2013;36(11):3786–3792. DOI: 10.2337/dc13-0102.
  51. Frith J, Day CP, Robinson L, et al. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010;52(1):112–116. DOI: 10.1016/j.jhep.2009.10.010.
  52. Hydes TJ, Ravi S, Loomba R, et al. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 2020;26(4):383–400. DOI: 10.3350/cmh.2020.0067.
  53. Benjaminov O, Beglaibter N, Gindy L, et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc 2007;21(8):1423–1427. DOI: 10.1007/s00464-006-9182-8.
  54. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011;53(5): 1504–1514. DOI: 10.1002/hep.24242.
  55. Westerbacka J, Lammi K, Häkkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90(5):2804–2809. DOI: 10.1210/jc.2004-1983.
  56. Lewis MC, Phillips ML, Slavotinek JP, et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg 2006;16(6):697–701. DOI: 10.1381/096089206777346682.
  57. Lin WY, Wu CH, Chu NF, et al. Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial. Nutrition 2009;25(11–12):1129–1136. DOI: 10.1016/j.nut.2009.02.008.
  58. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332(10): 621–628. DOI: 10.1056/NEJM199503093321001.
  59. Mazidi M, Katsiki N, Mikhailidis DP, et al. Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. Eur Heart J 2019;40(34):2870–2879. DOI: 10.1093/eurheartj/ehz174.
  60. Shan Z, Guo Y, Hu FB, et al. Association of low-carbohydrate and low-fat diets with mortality among US adults. JAMA Intern Med 2020;180(4):513–523. DOI: 10.1001/jamainternmed.2019.6980.
  61. Mardinoglu A, Wu H, Bjornson E, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab 2018;27(3):559–571.e5. DOI: 10.1016/j.cmet.2018.01.005.
  62. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013;339(6116):211–214. DOI: 10.1126/science.1227166.
  63. Tendler D, Lin S, Yancy WS, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007;52(2):589–593. DOI: 10.1007/s10620-006-9433-5.
  64. Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food 2011;14(7–8):677–680. DOI: 10.1089/jmf.2011.0075.
  65. Schiavo L, Pilone V, Rossetti G, et al. A 4-week preoperative ketogenic micronutrient-enriched diet is effective in reducing body weight, left hepatic lobe volume, and micronutrient deficiencies in patients undergoing bariatric surgery: a prospective pilot study. Obes Surg 2018;28(8):2215–2224. DOI: 10.1007/s11695-018-3145-8.
  66. Paoli A, Cenci L, Grimaldi KA. Effect of ketogenic Mediterranean diet with phytoextracts and low carbohydrates/high-protein meals on weight, cardiovascular risk factors, body composition and diet compliance in Italian council employees. Nutr J 2011;10:112. DOI: 10.1186/1475-2891-10-112.
  67. Bruci A, Tuccinardi D, Tozzi R, et al. Very low-calorie ketogenic diet: a safe and effective tool for weight loss in patients with obesity and mild kidney failure. Nutrients 2020;12(2):E333. DOI: 10.3390/nu12020333.
  68. Ministrini S, Calzini L, Nulli Migliola E, et al. Lysosomal acid lipase as a molecular target of the very low carbohydrate ketogenic diet in morbidly obese patients: the potential effects on liver steatosis and cardiovascular risk factors. J Clin Med 2019;8(5):E621. DOI: 10.3390/jcm8050621.
  69. Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Investig Med 2017;65(8):1102–1115. DOI: 10.1136/jim-2017-000524.
  70. Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients 2015;7(11):9127–9138. DOI: 10.3390/nu7115454.
  71. Kastorini CM, Milionis HJ, Esposito K, et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011;57(11): 1299–1313. DOI: 10.1016/j.jacc.2010.09.073.
  72. Blond E, Disse E, Cuerq C, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral. Diabetologia 2017;60(7):1218–1222. DOI: 10.1007/s00125-017-4264-9.
  73. Martinez-Gonzalez MA, Martin-Calvo N. Mediterranean diet and life expectancy; beyond olive oil, fruits, and vegetables. Curr Opin Clin Nutr Metab Care 2016;19(6):401–407. DOI: 10.1097/MCO.0000000000000316.
  74. Parnell JA, Raman M, Rioux KP, et al. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 2012;32(5):701–711. DOI: 10.1111/j.1478-3231.2011.02730.x.
  75. Gill S, Panda S. A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits. Cell Metab 2015;22(5):789–798. DOI: 10.1016/j.cmet.2015.09.005.
  76. Stekovic S, Hofer SJ, Tripolt N, et al. Alternate day fasting improves physiological and molecular markers of aging in healthy, non-obese humans. Cell Metab 2019;30(3):462–476.e6. DOI: 10.1016/j.cmet.2019.07.016.
  77. Zauner C, Schneeweiss B, Kranz A, et al. Resting energy expenditure in short-term starvation is increased as a result of an increase in serum norepinephrine. Am J Clin Nutr 2000;71(6):1511–1515. DOI: 10.1093/ajcn/71.6.1511.
  78. Yin C, Li Z, Xiang Y, et al. Effect of intermittent fasting on non-alcoholic fatty liver disease: systematic review and meta-analysis. Front Nutr 2021;8:709683. DOI: 10.3389/fnut.2021.709683.
  79. Ferguson B. ACSM's guidelines for exercise testing and prescription 9th Ed. 2014. J Can Chiropr Assoc 2014;58(3):328. PMCID: PMC4139760.
  80. Bowden Davies KA, Sprung VS, et al. Physical activity and sedentary time: association with metabolic health and liver fat. Med Sci Sports Exerc 2019;51(6):1169–1177. DOI: 10.1249/MSS.0000000000001901.
  81. Ryu S, Chang Y, Jung HS, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol 2015;63(5):1229–1237. DOI: 10.1016/j.jhep.2015.07.010.
  82. Healy GN, Dunstan DW, Salmon J, et al. Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care 2008;31(4):661–666. DOI: 10.2337/dc07-2046.
  83. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388–391. DOI: 10.1161/01.cir.0000020190.45892.75.
  84. Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41(2):459–471. DOI: 10.1249/MSS.0b013e3181949333.
  85. Liguori G. ACSM's guideline for exercise testing and prescription. 5th ed. Lippincott Willams and Wilkins; 2006.
  86. Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017;66(1):142–152. DOI: 10.1016/j.jhep.2016.08.023.
  87. Perri MG, Anton SD, Durning PE, et al. Adherence to exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and frequency. Health Psychol 2002;21(5):452–458. PMID: 12211512.
  88. Zhang HJ, He J, Pan LL, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med 2016;176(8):1074–1082. DOI: 10.1001/jamainternmed.2016.3202.
  89. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106(3):460–468; quiz 469. DOI: 10.1038/ajg.2010.488.
  90. Guiraud T, Nigam A, Juneau M, et al. Acute responses to high-intensity intermittent exercise in CHD patients. Med Sci Sports Exerc 2011;43(2):211–217. DOI: 10.1249/MSS.0b013e3181ebc5de.
  91. Gordon BA, Benson AC, Bird SR, et al. Resistance training improves metabolic health in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2009;83(2):157–175. DOI: 10.1016/j.diabres.2008.11.024.
  92. Schuenke MD, Mikat RP, McBride JM. Effect of an acute period of resistance exercise on excess post-exercise oxygen consumption: implications for body mass management. Eur J Appl Physiol 2002;86(5):411–417. DOI: 10.1007/s00421-001-0568-y.
  93. Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep 2019;1(6):468–479. DOI: 10.1016/j.jhepr.2019.10.008.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.